Form 4: Abbott Labs Director Roman Reports Stock Transactions
Statement of Changes in Beneficial Ownership
Michael F. Roman, a Director at Abbott Laboratories, reported transactions involving stock equivalent units on March 31, 2026.
Summary
- Michael F. Roman, a Director of Abbott Laboratories, filed a Form 4 reporting changes in his beneficial ownership of company securities.
- The filing details transactions related to stock equivalent units, which are credited to an account and paid out in cash upon retirement from the board or at age 65.
- These units earn returns equivalent to investing in Abbott shares.
- The report indicates the acquisition of 367 stock equivalent units on March 31, 2026.
- Following these transactions, Mr. Roman beneficially owns 6,283 stock equivalent units directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine insider transactions related to director compensation rather than significant strategic shifts or performance indicators.
Positives
- Director Michael F. Roman continues to hold a significant number of stock equivalent units, indicating ongoing commitment to the company.
- The stock equivalent units are designed to mirror the performance of Abbott shares, aligning the director's interests with those of shareholders.
- Dividend reinvestment features are included in the stock equivalent units, further enhancing potential returns.
Future Outlook
The stock equivalent units are designed to provide returns mirroring Abbott shares and are paid out in cash at a future date (age 65 or retirement), suggesting a long-term perspective for the director's compensation.
Industry Context
StockSavvy.ai notes that this Form 4 filing is a routine disclosure for directors and officers, reflecting standard corporate governance practices in the pharmaceutical and healthcare industry. Such filings provide transparency regarding insider holdings and transactions.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation Structure | Director fees are credited to a stock equivalent unit account, earning returns equivalent to Abbott shares, and paid in cash at a future date. | N/A (ongoing practice) | Aligns director compensation with shareholder interests and provides long-term incentive. |
Stakeholder Impact
- Shareholders: Increased transparency into director's holdings and alignment of interests.
- Employees: Indirectly reflects the company's compensation structure for its board members.
- Management: Standard reporting requirement, demonstrating adherence to SEC regulations.
Next Steps
- Director Michael F. Roman will continue to accrue stock equivalent units, which will be paid out in cash upon reaching age 65 or retiring from the board.
Key Dates
| Date | Description |
|---|---|
| 03/31/2026 | Earliest transaction date reported and date of acquisition of stock equivalent units. |
| 04/02/2026 | Date the Form 4 was signed by the reporting person's attorney-in-fact. |
Keywords
Abbott Laboratories, Form 4, Stock Equivalent Units, Director, Beneficial Ownership, Insider Trading, SEC Filing, Securities Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.